Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Sanofi teams with researchers to develop trispecific antibodies for HIV

Published 09/20/2017, 03:36 PM
Updated 09/20/2017, 03:36 PM
© Reuters. Sanofi teams with researchers to develop trispecific antibodies for HIV
  • A team of scientists from Sanofi (PA:SASY) (SNY), Harvard Medical School, NIAID, MIT, Harvard, The Scripps Research Institute and the Ragon Institute of Mass General Hospital have produced genetically engineered antibodies that exhibit unprecedented activity against the AIDS virus HIV-1.
  • The antibodies engage multiple targets, three to be exact, which enables them to be extraordinarily effective in suppressing virus growth and infection. The "trispecific" antibodies neutralized 99% of more than 200 diverse strains of HIV-1 in a study just published in the journal Science.
  • The trispecific antibodies are based on technology developed by Sanofi who is now manufacturing them for use in a Phase 1 study that will commence next year at NIH's National Institute of Allergy and Infectious Diseases (([NIAID)).
  • Now read: Sanofi (SNY) Presents At Bank of America Merrill Lynch (NYSE:BAC) 2017 Global Healthcare Conference - Slideshow


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.